AIM ImmunoTech (AIM) Stock Analysis & Winston Score

AIM ImmunoTech is a small biotechnology company focused on developing drugs to treat serious diseases, including certain cancers and viral infections. Its main product candidate is Ampligen (rintatolimod), a drug designed to boost the immune system. The company is working to get Ampligen approved as a treatment for conditions like ME/CFS (chronic fatigue syndrome) and has explored its use against various cancers and viruses. AIM ImmunoTech makes very little revenue and operates at a significant loss, funding itself primarily through stock offerings and grants rather than product sales. The company is based in Ocala, Florida, and operates almost entirely in the United States. Its financial metrics reflect a pre-commercial stage business with deeply negative margins. The central risk is that Ampligen has faced a long and difficult path through clinical trials and regulatory review, and the company's survival depends heavily on securing FDA approval or finding a larger partner to fund further development.